Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8288)	1/14/1999 11:52:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bob, have you seen the new XOMA Ltd. site? As far as I can tell the old XOMA Corp. site is no longer being updated. Last was on 7 Jan. Understand M. Murphy said DSMB will meet today or tomorrow and am assuming XOMA would have said something on its' site if true. I did not listen to his hotline, so this is hearsay. BTW do you think Robert S was successful in getting Blue Genes, or whatever, to get out of XOMA? Have not see his/her post for some time.

To: Robert K. who wrote (8288)	1/14/1999 4:20:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Have just heard that the Meningococcemia trial has accrued 333 patients. The last 12 came from the U.K. I don't know when the trial will end, but would think it will be soon, meaning a few more weeks. Few for me means 4 to 6. This is only my opinion, so it is worth even less than yours.<g> I remain more optimistic about XOMA than ever. I do not see a problem with the fact that accruals have continued past Dec. Do hope that XOMA clarifies this and I do wish the U.K. data on the PHLS site would update faster.